In this study, doctors from Japan examined the effect of the specific cyclooxygenase-2 inhibitor rofecoxib on rectal polyps in familial adenomatous polyposis patients.
The team randomly assigned 21 patients to receive either 25 mg rofecoxib per day or a placebo.
All patients underwent endoscopy at the beginning of the study, and then every 3 months thereafter.
The team reviewed the videotapes to measure the number and size of polyps throughout the study period.
|Polyp number significantly decreased in the rofecoxib group.|
|Clinical Cancer Research|
The polyp number was measured as a percentage of change from baseline.
The doctors found that polyp number significantly decreased in the rofecoxib group at 3, 6, and 9 months.
They determined that, at 9 months, polyp number in the rofecoxib group had decreased by 7%, whereas those in the placebo group had increased by 3%.
Furthermore, at 9 months, the team found that polyp size in the rofecoxib group had also reduced.
Dr Tetsuro Higuchi's team concluded, "Once-daily treatment with 25 mg rofecoxib…significantly decreased the number and size of rectal polyps in familial adenomatous polyposis patients".